Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
September 23, 2019

EASD 2019: ONSET 9 delivers positive data for Novo Nordisk’s Fiasp

Positive results were announced, indicating that Fiasp is a promising option for diabetes patients who require mealtime insulin.

By GlobalData Healthcare

Prandial insulin, such as Novo Nordisk’s NovoRapid/NovoLog (insulin aspart), is commonly prescribed to type 2 diabetes (T2D) patients who have difficulty lowering their blood glucose levels despite already being on oral diabetic therapy.

At the 55th annual European Association for the Study of Diabetes (EASD) meeting in Barcelona, Novo Nordisk’s Fiasp, an ultra-fast-acting insulin with an improved glucose-lowering effect compared to NovoRapid/NovoLog, was on the agenda.

Specifically, the focus was on the ONSET 9 trial, which evaluated the efficacy and safety of Fiasp compared with NovoRapid/NovoLog. Positive results were announced, indicating that Fiasp is a promising option for diabetes patients who require mealtime insulin.

The study was a 16-week, multicenter, double-blind, treat-to-target trial. Both treatment arms (Fiasp-treated and NovoRapid/NovoLog treated) were also treated with long-acting insulin, Novo Nordisk’s Tresiba (insulin degludec), with or without metformin. Trial results demonstrated a significant reduction from baseline hemoglobin A1c for T2D adult patients treated with Fisap compared to NovoRapid/NovoLog.

Specifically, Fiasp was deemed superior to NovoRapid/NovoLog given the significant reduction from baseline in one-hour postprandial glucose (PPG) following a meal test. Additionally, the overall lower rate of treatment-emergent severe blood glucose-confirmed hypoglycemia in Fiasp-treated patients versus patients treated with NovoRapid/NovoLog was statistically significant. A similar rate in the occurrence of severe hypoglycemia was observed within four hours after a meal.

In combination with Tresiba, Fiasp provided overall effective glycemic control, superior PPG control, and a lower rate of severe or blood glucose-confirmed hypoglycemia versus NovoRapid/NovoLog in T2D adults. Key opinion leaders interviewed by GlobalData previously indicated a preference for fast-acting insulin analogues (such as Fiasp) as part of a multiple-dose injection (MDI) therapy.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

These promising results will provide physicians with more confidence when prescribing Fiasp as part of MDI therapy. Furthermore, a survey conducted by GlobalData found that 30% of physicians would favour switching from rapid-acting insulin analogues to ultra-fast formulations of the same insulin type as part of MDI. However, the success in achieving this market dominance and a high prescriber rate will rest on pricing, especially considering that the current NovoRapid/NovoLog has a significant price tag.

Related Report
GlobalData (2019). Type 2 Diabetes – Global Drug Forecast and Market Analysis to 2028, to be published

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy